Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting &bgr;2-agonists: results of the pacman cohort

Author： Zuurhout Miranda JL   Vijverberg Susanne JH   Raaijmakers Jan AM   Koenderman Leo   Postma Dirkje S   Koppelman Gerard H   Maitland-van der Zee Anke Hilse  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.16, 2013-12, pp. : 1965-1971

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Inhaled corticosteroids plus long-acting &bgr;2-agonists as a combined therapy in asthma

By García-Marcos Luis   Schuster Antje   Barroso Nicolás Cobos  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 1, 2003-01 ,pp. : 23-39

Informa Healthcare

Access to resources Recommend Favorite

Advances in Asthma and COPD Treatment: Combination Therapy with Inhaled Corticosteroids and Long-Acting &bgr;2-Agonists.

By  

Current Pharmaceutical Design, Vol. 12, Iss. 25, 2006-01 ,pp. : 3261-3279

Bentham Science Publishers

Access to resources Recommend Favorite

ADRB2 Arg16 and the need for collaboration in childhood asthma pharmacogenomics

By Vijverberg Susanne JH   Raaijmakers Jan AM   Maitland-van der Zee Anke Hilse  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 1937-1939

Future Medicine

Access to resources Recommend Favorite

Long-acting &bgr;2 agonists: Pfizer’s development candidate?

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. : 1753-1757

Informa Healthcare

Access to resources Recommend Favorite

Long-acting β2 agonists

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite